Lung cancer research and treatment: global perspectives and strategic calls to action

This publication has 112 references indexed in Scilit:

• LBA67 A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
  Annals of Oncology, 2023
• LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
  Annals of Oncology, 2023
• 1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial
  Annals of Oncology, 2023
• SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
  Annals of Oncology, 2023
• Emerging Strategies for the Treatment of Small Cell Lung Cancer
  JAMA Oncology, 2023
• Evaluation of Lung Cancer Risk Among Persons Undergoing Screening or Guideline-Concordant Monitoring of Lung Nodules in the Mississippi Delta
  JAMA Network Open, 2023
• LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial
  Annals of Oncology, 2022
• Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
  Annals of Oncology, 2022
• Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
  Annals of Oncology, 2021
• Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
  Annals of Oncology, 2021